Prescribing Pattern of Chemotherapy Regimens In Breast Cancer

Cancer is a disease of abnormal, uncoordinated, uncontrolled and purposeless cell division in any part of body. The leading cause of death in women is due to breast cancer that accounts for 12.7% around the globe. This study aims to describe the prescribing trends and possible avenues for improving of chemotherapy drugs in breast cancer patients. The prospective observational was conducted among 178 patients in the Medical Oncological Department of Apollo Multispecialty Hospital and Research Center for a period of 6 months. The data was assessed and evaluated using statistical tool. The number of patients receiving adjuvant, neoadjuvant and palliative therapy was 131,10 and 37 respectively. The most commonly prescribed drug as monotherapy in adjuvant, neoadjuvant and palliative therapy was paclitaxel (14.5%) or zoledronic acid (14.5%), trastuzumab (40%) and zoledronate (45.9%) respectively. The most commonly prescribed combinational regimens drug in adjuvant, neoadjuvant and palliative therapy was Cyclophosphamide with Docetaxel (15.30%), Cyclophosphamide with Docetaxel (20%) or cyclophosphamide with Epirubicin (20%) and Letrozole with zoledronate (21.6%). Dexamethasone, ondansetron and pantoprazole (100%) were co administered in all the patients during their chemotherapy cycles. The observed side effects were back pain, anemia, neutropenia, insomnia, anxiety, myalgia, cough. The prescribed chemotherapy drugs for the breast cancer meet the criteria of patient’s adherence. Breast cancer is a prevalent type of cancer that require long term therapy and monitoring to evaluate and refine the therapeutic regimen of breast cancer to provide the extension and better quality of life.